menu
    • menu
    [{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Washington University School of Medicine | Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Washington University School of Medicine | Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Implicit Bioscience \/ Washington University School of Medicine | Cleveland Clinic"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Implicit Bioscience \/ University of Washington"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"University of Virginia | Virginia Commonwealth University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ University of Virginia | Virginia Commonwealth University","highestDevelopmentStatusID":"7","companyTruncated":"Implicit Bioscience \/ University of Virginia | Virginia Commonwealth University"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Royal Brisbane and Women's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Neurology","graph2":"Phase I","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Royal Brisbane and Women's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Implicit Bioscience \/ Royal Brisbane and Women's Hospital"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IC14","moa":"Monocyte differentiation antigen CD14","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IC14","moa":"Monocyte differentiation antigen CD14","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IC14","moa":"Monocyte differentiation antigen CD14","graph1":"Neurology","graph2":"Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"IC14","moa":"Monocyte differentiation antigen CD14","graph1":"Neurology","graph2":"Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"IC14","moa":"Monocyte differentiation antigen CD14","graph1":"Neurology","graph2":"Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Implicit Bioscience \/ Massachusetts General Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Implicit Bioscience

    Menu

    Implicit Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Washington University School of Medicine | Cleveland Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

                            Details : Atibuclimab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of ST Elevation Myocardial Infarction.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 07, 2024

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Washington University School of Medicine | Cleveland Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : University of Virginia | Virginia Commonwealth University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IC14 for Treatment of Acute Decompensated Heart Failure

                            Details : Atibuclimab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 16, 2024

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University of Virginia | Virginia Commonwealth University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : University of Washington

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

                            Details : Atibuclimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Distress Syndrome.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            July 22, 2024

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : University of Washington

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

                            Details : Atibuclimab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arrhythmogenic Right Ventricular Dysplasia.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 23, 2024

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC14

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical trial in COVID-19 patients tests anti-inflammatory drug developed 25 years ago at Scripps Research

                            Details : The trial will assess if IC14 can temper the immune system’s response to coronavirus infection of the lungs, thus preventing dangerous levels of inflammation.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 29, 2020

                            Lead Product(s) : IC14

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC14

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)

                            Details : IC14 is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 15, 2020

                            Lead Product(s) : IC14

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC14

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IC14 for ALS Patients Expanded Access

                            Details : IC14 is a Antibody drug candidate, which is currently being evaluated in clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 16, 2020

                            Lead Product(s) : IC14

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IC14 in Adult Patients With Dengue Fever

                            Details : Atibuclimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dengue.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 14, 2019

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC14

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IC14 for Treatment of Amyotrophic Lateral Sclerosis

                            Details : IC14 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 25, 2018

                            Lead Product(s) : IC14

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Implicit Bioscience

                            Australia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Royal Brisbane and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

                            Details : Atibuclimab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Motor Neuron Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 04, 2018

                            Lead Product(s) : Atibuclimab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Royal Brisbane and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth